Novellia Raises $18M Series A to Scale Its Patient‑powered Real‑world Data Platform

Why It Matters

By shifting data ownership to patients, Novellia could lower the $80‑100 million annual spend pharma firms incur on fragmented real‑world data while delivering higher‑quality insights for drug development and safety monitoring.

Key Takeaways

• Novellia raised $18M Series A, total funding $28M.
• Platform aggregates patient records, enabling consent‑based real‑world data.
• Pharma firms gain more accurate safety and efficacy insights.
• Patients use service free; revenue from anonymized data sales.
• Majority of top‑10 pharma companies already partnered with Novellia.

Pulse Analysis

The real‑world evidence (RWE) market has exploded as regulators and payers demand post‑approval safety and effectiveness data, yet traditional vendors still rely on brokered, often incomplete datasets. Fragmentation across hospitals, labs and specialty clinics forces pharmaceutical companies to spend upwards of $100 million a year stitching together patient journeys, a process riddled with consent gaps and transcription errors. Novellia’s model flips this paradigm by empowering individuals to pull their own longitudinal records and opt‑in to share de‑identified insights, promising a cleaner, more patient‑centric data pipeline.

For drug makers, the shift matters on two fronts. First, richer, consent‑based datasets improve signal detection for adverse events, as illustrated by Novellia’s analysis that lowered the perceived risk of a breast‑cancer therapy. Second, the platform’s free‑to‑patient interface eliminates acquisition costs, allowing pharma to reallocate budget toward higher‑impact research activities. By validating data across multiple sources, Novellia also uncovers provider‑level errors that conventional RWE solutions miss, enhancing the credibility of outcomes studies and supporting more precise market access strategies.

The $18 million Series A, led by Spark Capital, signals strong investor confidence in patient‑driven data ecosystems. With backing from Khosla Ventures and other deep‑tech funds, Novellia is positioned to scale its technology amid tightening interoperability mandates such as the 21st Century Cures Act. As more top‑tier pharma companies adopt the platform, the competitive pressure on legacy RWE vendors will intensify, potentially accelerating industry-wide moves toward consent‑first data architectures and reshaping the economics of healthcare research.

Deal Summary

New York‑based health data startup Novellia closed a $18 million Series A round, bringing its total funding to $28 million. The round was led by Spark Capital with participation from Khosla Ventures, TMV, Acrew Capital and Bling Capital. The capital will help scale its patient‑permissioned real‑world data platform for pharma research.